Technical Data
T9160-41F
Tumor Necrosis Factor beta, Recombinant, Human (TNF-beta, TNFb, Lymphotoxin-alpha, LT-alpha, LTA, LT, Tumor Necrosis Factor Ligand Superfamily Member 1, TNFSF1)
20ug
Growth Factors, Cytokines Storage: -20CShipping: Blue Ice
Source:
Recombinant corresponding to 171aa of human Tumor Necrosis Factor-beta (Lymphotoxin) expressed in E. coli is a non-glycosylated, polypeptide chain.

Molecular Weight:
~18.6kD

Biological Activity:
The ED50 as determined by the cytolysis of mouse L929 cells in the presence of Actinomycin D is less then 0.05ng/ml, corresponding to a Specific Activity of 2x10 IU/mg.

Dimers and Aggregates:
1% (SDS-PAGE)

Protein Content:
Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm using the absorbency value of 1.082 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENEcomputer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a calibrated solution of TNF-beta as a Reference Standard.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
~18.6kD
Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug)
Concentration: Not determined
Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Association of TNF-alpha and TNF-beta gene polymorphism with steroid receptor expression in breast cancer patients. Pathol Oncol Res 2005;11(2):99-102. 2. Polymorphism in the genes of alpha and beta tumor necrosis factors (TNF-alpha and TNF-beta) and gamma interferon (IFN-gamma) among Iranian women with breast cancer. Cancer Lett 2005 Jun 1;223(1):113-9. 3. Genetic polymorphisms of TGF-beta1 & TNF-beta and breast cancer risk. Breast Cancer Res Treat 2005 Mar;90(2):149-55. 4. TNF-alpha-, TNF-beta-, IL-6-, and IL-10-promoter polymorphisms in patients with chronic obstructive pulmonary disease. Tissue Antigens 2005 Jan;65(1):93-100. 5. Polymorphisms within the genes encoding TNF-alpha and TNF-beta associate with the incidence of post-transplant complications in r ecipients of allogeneic hematopoietic stem cell transplants. Arch Immunol Ther Exp (Warsz) 2004 Jul-Aug;52(4):240-9. 6. Genetic polymorphisms in tumor necrosis factor (TNF)-alpha and TNF-beta in a population-based study of systemic lupus erythematosus: associations and interaction with the interleukin-1alpha-889 C/T polymorphism. Hum Immunol 2004 Jun;65(6):622-31.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.